Whalesbook
Alivus Life Sciences: Record Quarter Driven by Margin Expansion, Guidance Lifted
The Numbers:
Alivus Life Sciences reported a stellar Q3 FY'26, achieving its highest-ever quarterly revenue of Rs. 673 crores. This represents a 4.8% year-on-year (YoY) and 14.4% quarter-on-quarter (QoQ) growth. Profitability saw a dramatic uplift, with EBITDA margins reaching an all-time high of 36.4%, an impressive increase of 510 basis points YoY and 340 bps QoQ. Gross margins also improved to 58.9%. Profit After Tax (PAT) for the quarter stood at Rs. 150 crores.
For the nine months ended December 31, 2025, revenue grew by 7.2% YoY to Rs. 1,863 crores. EBITDA for the period was Rs. 620 crores, up 22% YoY, with margins at 33.3% (up 400 bps YoY). PAT for the nine months was Rs. 402 crores, translating to a 21.6% PAT margin.
The Quality:
The company continues its strong financial trajectory, maintaining its net debt-free status. Free cash flow generation remains robust, with Rs. 221 crores reported for the nine-month period. Cash and cash equivalents stood at a healthy Rs. 733 crores as of December 31, 2025. R&D expenditure for Q3 FY'26 was Rs. 23 crores, representing 3.4% of sales, indicating continued investment in innovation.
The Grill:
While the earnings call featured management providing positive outlook and guidance, there were no significant instances of an analyst "grill" or controversial statements. Management clearly articulated reasons for minor project delays and provided updated timelines and CAPEX plans.
Risks & Outlook:
Management has provided a positive outlook, highlighted by a raised EBITDA margin guidance for the future to a range of 30%-32% (up from 28%-30%). This is driven by operational efficiencies, new product introductions, and a favorable product mix. The company anticipates high single-digit revenue growth for FY'26 and FY'27, with expectations of achieving double-digit growth from FY'28-'29. A minor delay of approximately three months has affected the Solapur expansion project, now expected to commence operations by July 2026. However, brownfield expansions at Ankleshwar and Dahej are progressing as planned and are slated for Q2 FY'27 operational start. The CDMO segment is showing a strong recovery and growth, with management confident in securing new projects.
General risks like the geopolitical situation and pricing erosion were acknowledged but are being actively managed through diversified presence and next-generation processes. The company's long-term strategy focuses on cash generation and disciplined capital deployment for potential inorganic expansion, leveraging strengths in API generics and CDMO services.